Norethisterone acetate oxime
Norethisterone acetate oxime (developmental code names ORF-5263, So-36), or norethindrone acetate oxime, is a steroidal progestin of the 19-nortestosterone group which was developed as a postcoital contraceptive but was never marketed.[1] It is the C3 oxime and C17β-acetate ester of norethisterone.[1]
 | |
| Clinical data | |
|---|---|
| Other names | Norethindrone acetate oxime; ORF-5263; So-36; Norethisterone-3-oxime acetate; 17α-Ethynyl-19-nortestosterone 3-oxime 17β-acetate |
| Routes of administration | By mouth |
| Drug class | Progestogen; Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H29NO3 |
| Molar mass | 355.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 886–. ISBN 978-1-4757-2085-3.
| AR |
| ||||||
|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||
| |||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.